Free  Leave my placenta alone!

Marketing Authorisations

Birch bark extract cutaneous gel (Filsuvez°) in epidermolysis bullosa

Olaparib (Lynparza°) as adjuvant treatment for certain breast cancers with a BRCA mutation

Olaparib (Lynparza°) as "maintenance" therapy for certain advanced ovarian cancers after first-line chemotherapy

Editors' opinion. New data

Avalglucosidase alfa (Nexviadyme°) in Pompe disease

Asciminib (Scemblix°) in chronic myeloid leukaemia

Teclistamab (Tecvayli°) in multiple myeloma after several lines of treatment

Brolucizumab (Beovu°) in diabetic macular oedema

Ambrisentan (Volibris° or other brands) in pulmonary arterial hypertension from 8 years of age

Pembrolizumab (Keytruda°) as second- or subsequent-line treatment for various cancers with DNA repair defects

Editors' opinion. Another marketing authorisation based on an unethical evaluation!

Sublingual sufentanil (Dzuveo°) for acute pain

Adverse Effects

Drugs that interfere with the placenta and affect the fetus

Clomifene: serious, sometimes irreversible, vision disorders

Crizotinib and sofosbuvir + velpatasvir: increased risk of heart failure and bradycardia

Cyproheptadine to gain weight: a high-risk use

Common stem: -fentanil

Outlook

Free  Towards better patient care: drugs to avoid in 2024

Inset. Main changes in the 2024 update of Prescrire's drugs to avoid

Free  European Commission: taken to task by the Ombudsman for lack of transparency

Free  Revision of European pharmaceutical legislation

Masthead

Free  Masthead